ATE120201T1 - Anti-sens nukleotidsequenz, anti-rns des alpha- tnfs, verfahren zu deren herstellung und deren verwendung als arzneimittel und pharmazeutische präparate davon. - Google Patents

Anti-sens nukleotidsequenz, anti-rns des alpha- tnfs, verfahren zu deren herstellung und deren verwendung als arzneimittel und pharmazeutische präparate davon.

Info

Publication number
ATE120201T1
ATE120201T1 AT90402329T AT90402329T ATE120201T1 AT E120201 T1 ATE120201 T1 AT E120201T1 AT 90402329 T AT90402329 T AT 90402329T AT 90402329 T AT90402329 T AT 90402329T AT E120201 T1 ATE120201 T1 AT E120201T1
Authority
AT
Austria
Prior art keywords
pharmaceutical preparations
tnfs
sens
rns
alpha
Prior art date
Application number
AT90402329T
Other languages
English (en)
Inventor
Abdel Karim Braham
Pierre Smets
Rene Zalisz
Original Assignee
Roussel Uclaf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf filed Critical Roussel Uclaf
Application granted granted Critical
Publication of ATE120201T1 publication Critical patent/ATE120201T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02K—DYNAMO-ELECTRIC MACHINES
    • H02K2203/00—Specific aspects not provided for in the other groups of this subclass relating to the windings
    • H02K2203/03—Machines characterised by the wiring boards, i.e. printed circuit boards or similar structures for connecting the winding terminations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Thin Magnetic Films (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
AT90402329T 1989-08-23 1990-08-22 Anti-sens nukleotidsequenz, anti-rns des alpha- tnfs, verfahren zu deren herstellung und deren verwendung als arzneimittel und pharmazeutische präparate davon. ATE120201T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8911171A FR2651130B1 (fr) 1989-08-23 1989-08-23 Sequence d'oligonucleotides anti-sens, anti-arn message du tnf alpha, procede de preparation, application a titre de medicaments et compositions pharmaceutiques.

Publications (1)

Publication Number Publication Date
ATE120201T1 true ATE120201T1 (de) 1995-04-15

Family

ID=9384878

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90402329T ATE120201T1 (de) 1989-08-23 1990-08-22 Anti-sens nukleotidsequenz, anti-rns des alpha- tnfs, verfahren zu deren herstellung und deren verwendung als arzneimittel und pharmazeutische präparate davon.

Country Status (19)

Country Link
US (1) US5705389A (de)
EP (1) EP0414607B1 (de)
JP (1) JPH0391485A (de)
KR (1) KR0151153B1 (de)
CN (1) CN1028760C (de)
AT (1) ATE120201T1 (de)
AU (1) AU642423B2 (de)
CA (1) CA2023899C (de)
DE (1) DE69017983T2 (de)
DK (1) DK0414607T3 (de)
ES (1) ES2069715T3 (de)
FR (1) FR2651130B1 (de)
GR (1) GR3015527T3 (de)
HU (1) HU215242B (de)
IE (1) IE68592B1 (de)
IL (1) IL95342A (de)
PT (1) PT95067B (de)
RU (1) RU2066325C1 (de)
ZA (1) ZA906675B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1250722B (it) * 1991-07-30 1995-04-21 Univ Degli Studi Milano Oligonucleotidi antisenso
TW323284B (de) * 1992-03-23 1997-12-21 Novartis Ag
EP0682705A1 (de) * 1993-02-03 1995-11-22 N.V. Innogenetics S.A. TNF - Alpha - Muteine und Verfahren zu deren Herstellung
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
AU1249299A (en) * 1997-11-25 1999-06-15 Brax Genomics Limited Chimeric antisense oligonucleotides against tnf-alpha and their uses
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US20040006036A1 (en) * 2000-04-12 2004-01-08 Gmr, A Delaware Corporation Silencing transcription by methylation
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
NZ598346A (en) * 2002-07-19 2013-10-25 Abbvie Biotechnology Ltd Treatment of tnf alpha related disorders
WO2006041970A2 (en) * 2004-10-08 2006-04-20 Abbott Biotechnology Ltd. Treatment of respiratory syncytial virus (rsv) infection
KR101465456B1 (ko) 2005-05-16 2014-11-27 애브비 바이오테크놀로지 리미티드 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
EP2010214A4 (de) 2006-04-10 2010-06-16 Abbott Biotech Ltd Verwendung und zusammensetzungen zur behandlung von rheumatoider arthritis
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2666472A3 (de) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Anwendungen und Zusammensetzungen zur Behandlung von Psoriasis-Arthritis
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
EP2171451A4 (de) 2007-06-11 2011-12-07 Abbott Biotech Ltd Verfahren zur behandlung juveniler idiopathischer arthritis
CN101235064B (zh) * 2008-02-27 2011-08-10 东南大学 可脱保护的硫代核苷酸单体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0090789A1 (de) * 1982-03-26 1983-10-05 Monsanto Company Chemische DNA-Synthese
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
FR2584090B1 (fr) 1985-06-27 1987-08-28 Roussel Uclaf Nouveaux supports, leur preparation et les intermediaires obtenus, leur application a la synthese d'oligonucleotides et les nouveaux nucleosides et oligonucleotides relies aux supports ainsi obtenus
WO1988006625A2 (en) * 1987-02-26 1988-09-07 Cetus Corporation Arginine-depleted human tumor necrosis factor
ATE137806T1 (de) * 1988-07-05 1996-05-15 Baylor College Medicine Verfahren zur identifizierung von bakterien

Also Published As

Publication number Publication date
HUT56113A (en) 1991-07-29
FR2651130A1 (fr) 1991-03-01
EP0414607A3 (en) 1991-04-03
KR910004198A (ko) 1991-03-28
IL95342A0 (en) 1991-06-30
GR3015527T3 (en) 1995-06-30
IE903036A1 (en) 1991-02-27
DE69017983D1 (de) 1995-04-27
FR2651130B1 (fr) 1991-12-13
CA2023899A1 (fr) 1991-02-24
CN1049668A (zh) 1991-03-06
IE68592B1 (en) 1996-06-26
DE69017983T2 (de) 1995-09-28
CA2023899C (fr) 2002-05-14
PT95067B (pt) 1997-05-28
DK0414607T3 (da) 1995-06-06
EP0414607A2 (de) 1991-02-27
AU642423B2 (en) 1993-10-21
JPH0391485A (ja) 1991-04-17
HU905302D0 (en) 1991-02-28
CN1028760C (zh) 1995-06-07
ES2069715T3 (es) 1995-05-16
HU215242B (hu) 1998-11-30
PT95067A (pt) 1991-04-18
US5705389A (en) 1998-01-06
EP0414607B1 (de) 1995-03-22
RU2066325C1 (ru) 1996-09-10
IL95342A (en) 1995-01-24
AU6119090A (en) 1991-02-28
KR0151153B1 (ko) 1998-08-17
ZA906675B (en) 1991-10-30

Similar Documents

Publication Publication Date Title
ATE120201T1 (de) Anti-sens nukleotidsequenz, anti-rns des alpha- tnfs, verfahren zu deren herstellung und deren verwendung als arzneimittel und pharmazeutische präparate davon.
DE3280400D1 (de) Oligonukleotides heilmittel und dessen herstellungsverfahren.
KR920700201A (ko) 신규 1α-히드록시비타민D 2 에피머 및 유도체
DE69025920T2 (de) Glykosaminoglykan-modifiertes Protein, Verfahren zu dessen Herstellung und pharmazeutische Zubereitungen, die es enthalten
GR3020098T3 (en) 11-Beta-aryl-4-estrene, method for its production and its use as a medicine
ATE328074T1 (de) Oligonukleotide die eine antisense-sequenz enthalten die durch eine sekondärstruktur stabilisiert sind und pharmazeutische zusammensetzungen die sie enthalten
FR2642065B1 (fr) Derives d'acides benzocycloalcenyl dihydroxy alcanoiques, procede de preparation et medicaments les contenant
DE59601683D1 (de) Sulfamat-derivate von 1,3,5(10)-estratrien-derivaten, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
HUT58037A (en) Process for producing n-2,3-butadienyl tri- and tetraaminoalkane derivatives
ATE100095T1 (de) 2,2-dimethylchromenderivate, verfahren zur herstellung und diese enthaltende pharmazeutische zusammenstellungen.
ATE104300T1 (de) Thieno(2,3-d>azepinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
ATE44950T1 (de) Polyprenylverbindungen, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
OA08734A (fr) Dérivés d'hydrazine, procédé d'obtention et compositions pharmaceutiques les contenant.
FR2830252B1 (fr) Nouveaux oligomeres d'urees, leur procede de preparation et compositions pharmaceutiques les contenant
FR2617403B1 (fr) Procede de preparation de derives des acides nucleiques et procede de preparation d'une composition medicale les contenant
ATE60333T1 (de) D-nor-7-ergolinderivate, verfahren zu ihrer herstellung, pharmazeutische zubereitung und verwendung.
FR2701952B1 (fr) Nouveaux dérivés cyclopeptidiques de l'angiopeptine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
ATE61222T1 (de) Aspoxicillin enthaltende medizinalzubereitung, ein verfahren zu ihrer herstellung und ihre verwendung zur herstellung eines arzneimittels.
DE3674250D1 (de) Phenylpyrazinderivate, verfahren zu deren herstellung, pharmazeutische zusammensetzung und verwendung.
FR2692899B1 (fr) Nouveaux dérivés peptidiques actifs dans les processus d'adhésion cellulaire, leur procédé de préparation et les compositions pharmaceutiques qui les renferment.
DE69102082T2 (de) Ungesättigte Gallsäurederivate, Verfahren zu ihrer Herstellung und pharmazeutische Präparate diese enthaltend.
ATE95174T1 (de) 1,4-dihydropyridin-derivate, verfahren zu ihrer herstellung, pharmazeutische zusammensetzung und ihre verwendung.
ATE94883T1 (de) Salze von glykosaminoglykanen, verfahren zu ihrer herstellung und diese salze enthaltende pharmazeutische zusammensetzungen.
ATE58540T1 (de) Substituierte 1,8-naphthyridinone, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE73131T1 (de) Alkansulfonanilid-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time